EGFR and non-small cell lung carcinoma: Several small prospective trials have shown that LCT, like surgery or stereotactic body radiation therapy (SBRT), can prolong PFS in patients with NSCLC and delay drug resistance in EGFR-TKIs when patients develop oligoprogression, oligometastases or oligopersistence [11, 12].